Mineralys Therapeutics (MLYS) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 35.4% versus a loss of 40.3%. Pharvaris N.V. is the larger company by market cap ($2.18 billion vs $2.07 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | PHVS |
|---|---|---|
| Share price | $23.37 | $31.10 |
| Market cap | $2.07B | $2.18B |
| 1-day change | +4.42% | -0.06% |
| YTD return | -38.33% | +12.14% |
| 1-year return | -40.30% | +35.42% |
| 5-year return | — | +96.96% |
| EPS (TTM) | $-4.22 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-154.65M | $-25.99M |
| 52-week high | $47.65 | $43.25 |
| 52-week low | $21.46 | $20.65 |
| Distance from 52-week high | -50.95% | -28.09% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +107.53% | +83.99% |
| Average volume | 1.04M | 711.75K |
| Shares outstanding | 88.41M | 70.20M |
| Employees | 76 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed MLYS by 75.7 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
MLYS vs PHVS FAQ
Which is bigger, Mineralys Therapeutics or Pharvaris N.V.?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.18B compared with $2.07B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or PHVS?
PHVS returned +35.42% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.